Temperature selection of intravesical sodium hyaluronate in the treatment of interstitial cystitis
10.12092/j.issn.1009-2501.2020.04.015
- VernacularTitle: 膀胱灌注透明质酸钠治疗间质性膀胱炎的温度选择
- Author:
Jiangyi CAI
1
Author Information
1. Department of Urinary Surgery, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine
- Publication Type:Journal Article
- Keywords:
Bladder perfusion;
Different temperatures;
Interstitial bladder symptoms score;
Interstitial cystitis;
Interstitial cystitis problem score;
Mast cells;
Sodium hyaluronate
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2020;25(4):447-454
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To investigate the efficacy of bladder infusion of sodium hyaluronate (HA) in the treatment of interstitial cystitis (IC) at different temperatures. METHODS: Forty patients with IC admitted in our hospital from March 2018 to April 2019 were simply randomized and divided into two groups for prospective study, with 20 patients in each group. The temperature of perfusion fluid in normal temperature group was 37 ℃, and the temperature of perfusion fluid in high temperature group was 43 ℃. Compared the two groups before treatment, one month after treatment, and three months after treatment of interstitial cystitis problem score (ICPI), interstitial bladder symptoms score (ICSI), pre-veeing pain visual analogue score (VAS), and anxiety self-assessment scale (SAS), depression self-assessment scale (SDS), quality of life score (QOL), daily urination times, maximum bladder volume, bladder mast cell count, and immune factors [interleukin (IL)-6, IL-10] expression. RESULTS:The ICPI, ICSI, VAS, SAS, and SDS scores of the hyperthermia group were lower than those of the normal temperature group after one month and three months of treatment, and the QOL scores were higher than those of the normal temperature group after three months of treatment (P<0.05). After one month and three months of treatment in the hyperthermia group, the daily urination frequency was lower than that in the normal temperature group, and the maximum bladder capacity after three months of treatment was greater than the normal temperature group (P<0.05). After three months of treatment in the hyperthermia group, the mast cell counts in the bladder mucosa were lower than those in the normal temperature group (P<0.05). IL-6 and IL-10 in the bladder mucosa were lower than those in the normal temperature group after three months of treatment in the high temperature group (P<0.05). There was no significant difference in the incidence of adverse reactions (0, 5.00%) between the two groups (P>0.05). CONCLUSION:Compared with 37 ℃, intravesical instillation of HA in the treatment of IC can effectively relieve the clinical symptoms and signs of patients when the perfusion fluid is at a temperature of 43 ℃, and it improves the maximum bladder capacity and anxiety and depression, improves the quality of life of patients, which is safe and reliable. The mechanism may be related to the regulation of large cell, IL-6, IL-10 of bladder mucosa.
